Docetaxel and Its Nanoformulations: How Delivery Strategies Could Impact the Therapeutic outcome?

Sharma, Saurabh; Pukale, Sudeep Sudesh; Mittal, Anupama

doi:10.4155/tde-2020-0088

Cited by 6 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on a comparison of MR data taken before and after treatment in a synthetic breast cancer model, the TPPS-RMANCH nanosystem showed sensitivity to ultrasound. The 4-sulfophenyl porphyrin and polymethyl methacrylate carried by the TPPS-RMANCH nanosystem can work as an anticancer agent in ultrasound therapy by combining their effects, suggesting that this multimodal system could be successfully used as a selective external control tool for cancer control [ 29 ].…”

Section: Resultsmentioning

confidence: 99%

Big Data Analysis of Manufacturing and Preclinical Studies of Nanodrug-Targeted Delivery Systems: A Literature Review

Cao

Li²,

Zhang

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Objective. Nanodelivery is a modern technology involving improved delivery methods and drug formulations. The current development and initial applications of nanocarriers are pointing to new directions in the current development of nanomedicine. Researchers are increasingly applying nanodelivery to the delivery of therapeutic or diagnostic agents. This article discusses the preparation and application of nanocomplexes and nanoparticles, as well as their potential future value in clinical research. Through a review and analysis, it is hoped that this will serve as a guide for the future development of various nanodelivery technologies and help researchers learn more about these technologies. Materials and Methods. A literature search was conducted using the keywords “Nano drug delivery” or “Nanomedical materials” or “Nano”. A literature search was conducted in three major databases, PubMed, Web of Science, and Google Scholar, using the keywords such as “Nano drug delivery”, “Nanomedical materials”, or “Nanobubble drug delivery”. The initial search was screened by title and abstract. In the full-text review, the titles or abstracts were reviewed according to the selection criteria based on the inclusion criteria. The risk of bias and study quality was assessed according to the Cochrane guidelines, and possible biases such as selection bias and good selection bias were included in the review. Results. A total of 297 studies were included in this study, of which 219 were excluded based on the screening criteria, resulting in the inclusion of 78 studies, the majority of which were original studies and clinical trials, and a small number of which provided design and route of administration analysis of nanomaterial particles and effect fluorograms and were studied in more depth. This paper summarises and reviews the views and directions of the included articles. The main directions include cyclodextrin-based or grafted cyclodextrin nanomaterials, nanobubbles, and stimuli-sensitive and temperature-sensitive nanodelivery systems. Conclusion. The use of innovative, targeted drug delivery systems is effective in cancer drug delivery by summarising the previous studies. However, nanodelivery systems’ risks and therapeutic effects need to be evaluated before clinical application. Future research in the field of targeted drug delivery nanosystems should focus on the development of nanocarriers with high in vivo delivery capacity, good synergy with therapeutic agents, and milder short-term and long-term toxicological effects and conduct comprehensive preclinical trials on nanodrug delivery systems with high potential for clinical application as soon as possible, to find nanodrug delivery systems suitable for clinical use and put them into the clinical application as soon as possible.

show abstract

Section: Resultsmentioning

confidence: 99%

Big Data Analysis of Manufacturing and Preclinical Studies of Nanodrug-Targeted Delivery Systems: A Literature Review

Cao

Li²,

Zhang

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…These pharmaceutical approaches have been successful in some cases; paclitaxel was first approved for oral administration in a lipid formulation by Korea for gastric cancer 43 . Several other pharmaceutical approaches to improve taxane bioavailability are in development 33 including a nanoparticle formulation of docetaxel (CPC634) 44 . These pharmaceutical strategies have complemented boosting strategies using inhibitors of putative drug transporters and DMEs.…”

Section: Intentional Use Of Drug–drug Interactions To Increase Bioavailabilitymentioning

confidence: 99%

Boosting the oral bioavailability of anticancer drugs through intentional drug–drug interactions

Eisenmann

Talebi

Sparreboom

et al. 2021

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Oral anticancer drugs suffer from significant variability in pharmacokinetics and pharmacodynamics partially due to limited bioavailability. The limited bioavailability of anticancer drugs is due to both pharmaceutical limitations and physiological barriers. Pharmacokinetic boosting is a strategy to enhance the oral bioavailability of a therapeutic drug by inhibiting physiological barriers through an intentional drug–drug interaction (DDI). This type of strategy has proven effective across several therapeutic indications including anticancer treatment. Pharmacokinetic boosting could improve anticancer drugs lacking or with otherwise unacceptable oral formulations through logistic, economic, pharmacodynamic and pharmacokinetic benefits. Despite these benefits, pharmacokinetic boosting strategies could result in unintended DDIs and are only likely to benefit a limited number of targets. Highlighting this concern, pharmacokinetic boosting has mixed results depending on the boosted drug. While pharmacokinetic boosting did not significantly improve certain drugs, it has resulted in the commercial approval of boosted oral formulations for other drugs. Pharmacokinetic boosting to improve oral anticancer therapy is an expanding area of research that is likely to improve treatment options for cancer patients.

show abstract

“…Docetaxel (DTX), a semisynthetic derivative of paclitaxel, is one of the most efficient anticancer drugs. 28 However, its clinical application is greatly restricted by its poor aqueous solubility, low permeability, and undesirable side effects. 29 To overcome these drawbacks, much attention has been focused on novel nanomaterial-based DTX formulations, such as intelligent polymeric micelles, 30 solid lipid nanoparticles, 31 chitosan-based nanoparticles, 32 hybrid nanocarriers, 33 , 34 and inorganic nanoparticles.…”

Section: Introductionmentioning

confidence: 99%

“…Docetaxel (DTX), a semisynthetic derivative of paclitaxel, is one of the most efficient anticancer drugs . However, its clinical application is greatly restricted by its poor aqueous solubility, low permeability, and undesirable side effects .…”

Section: Introductionmentioning

confidence: 99%

Rational Fabrication of Folate-Conjugated Zein/Soy Lecithin/Carboxymethyl Chitosan Core–Shell Nanoparticles for Delivery of Docetaxel

Zhang

et al. 2022

ACS Omega

View full text Add to dashboard Cite

The objective of this work is to design and fabricate a natural zein-based nanocomposite with core–shell structure for the delivery of anticancer drugs. As for the design, folate-conjugated zein (Fa-zein) was synthesized as the inner hydrophobic core; soy lecithin (SL) and carboxymethyl chitosan (CMC) were selected as coating components to form an outer shell. As for fabrication, a novel and appropriate atomizing/antisolvent precipitation process was established. The results indicated that Fa-zein/SL/CMC core–shell nanoparticles (FZLC NPs) were successfully produced at a suitable mass ratio of Fa-zein/SL/CMC (100:30:10) and the freeze-dried FZLC powder showed a perfect redispersibility and stability in water. After that, docetaxel (DTX) as a model drug was encapsulated into FZLC NPs at different mass ratios of DTX to FZLC ( MR ). When MR = 1:15, DTX/FZLC NPs were obtained with high encapsulation efficiency (79.22 ± 0.37%), small particle size (206.9 ± 48.73 nm), and high zeta potential (−41.8 ± 3.97 mV). DTX was dispersed in the inner core of the FZLC matrix in an amorphous state. The results proved that DTX/FZLC NPs could increase the DTX dissolution, sustain the DTX release, and enhance the DTX cytotoxicity significantly. The present study provides insight into the formation of zein-based complex nanocarriers for the delivery of anticancer drugs.

show abstract

Docetaxel and Its Nanoformulations: How Delivery Strategies Could Impact the Therapeutic outcome?

Cited by 6 publications

References 38 publications

Big Data Analysis of Manufacturing and Preclinical Studies of Nanodrug-Targeted Delivery Systems: A Literature Review

Big Data Analysis of Manufacturing and Preclinical Studies of Nanodrug-Targeted Delivery Systems: A Literature Review

Boosting the oral bioavailability of anticancer drugs through intentional drug–drug interactions

Rational Fabrication of Folate-Conjugated Zein/Soy Lecithin/Carboxymethyl Chitosan Core–Shell Nanoparticles for Delivery of Docetaxel

Contact Info

Product

Resources

About